BE1002159A5 - Adsorbats medicamenteux. - Google Patents

Adsorbats medicamenteux. Download PDF

Info

Publication number
BE1002159A5
BE1002159A5 BE8900501A BE8900501A BE1002159A5 BE 1002159 A5 BE1002159 A5 BE 1002159A5 BE 8900501 A BE8900501 A BE 8900501A BE 8900501 A BE8900501 A BE 8900501A BE 1002159 A5 BE1002159 A5 BE 1002159A5
Authority
BE
Belgium
Prior art keywords
adsorbates
medicinal
absorbates
aqueous
ranitidine
Prior art date
Application number
BE8900501A
Other languages
English (en)
Inventor
Stephen John Douglas
Fiona Ruth Bird
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB888811167A external-priority patent/GB8811167D0/en
Priority claimed from GB888816185A external-priority patent/GB8816185D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of BE1002159A5 publication Critical patent/BE1002159A5/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)

Abstract

Conformément à la présente invention, les absorbats sont constitués par des complexes formés entre la ranitidine et une résine synthétique échangeuse de cations. Ces absorbats sont particulièrement appropriés pour l'utilisation dans des compositions pharmaceutiques pour administration orale, telles que comprimés à croquer ou à sucer, granules et suspensions aqueuses ou non aqueuses.
BE8900501A 1988-05-11 1989-05-10 Adsorbats medicamenteux. BE1002159A5 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB888811167A GB8811167D0 (en) 1988-05-11 1988-05-11 Medicaments
GB888816185A GB8816185D0 (en) 1988-07-07 1988-07-07 Medicaments

Publications (1)

Publication Number Publication Date
BE1002159A5 true BE1002159A5 (fr) 1990-08-14

Family

ID=26293879

Family Applications (1)

Application Number Title Priority Date Filing Date
BE8900501A BE1002159A5 (fr) 1988-05-11 1989-05-10 Adsorbats medicamenteux.

Country Status (35)

Country Link
US (1) US5032393A (fr)
JP (1) JP2944678B2 (fr)
KR (1) KR890016968A (fr)
CN (1) CN1027133C (fr)
AT (1) AT401614B (fr)
AU (1) AU624613B2 (fr)
BE (1) BE1002159A5 (fr)
CA (1) CA1337272C (fr)
CH (1) CH679011A5 (fr)
CY (1) CY1781A (fr)
DE (1) DE3915347C2 (fr)
DK (1) DK168934B1 (fr)
ES (1) ES2011573A6 (fr)
FI (1) FI92060C (fr)
FR (1) FR2631232B1 (fr)
GB (1) GB2218333B (fr)
GR (1) GR1000358B (fr)
HK (1) HK45094A (fr)
HU (2) HU204994B (fr)
IE (1) IE60722B1 (fr)
IL (1) IL90245A (fr)
IT (1) IT1232831B (fr)
LU (1) LU87515A1 (fr)
MX (1) MX173349B (fr)
MY (1) MY104013A (fr)
NL (1) NL8901188A (fr)
NO (1) NO175131C (fr)
NZ (1) NZ229064A (fr)
PH (1) PH27612A (fr)
PL (1) PL279377A1 (fr)
PT (1) PT90523B (fr)
RU (1) RU2033155C1 (fr)
SE (1) SE508343C2 (fr)
SG (1) SG48194G (fr)
YU (1) YU47674B (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219563A (en) * 1988-05-11 1993-06-15 Glaxo Group Limited Drug adsorbates
CA2002492A1 (fr) * 1988-11-11 1990-05-11 Sandra T. A. Malkowska Compose pharmaceutique contenant une resine echangeuse d'ions
GB8904182D0 (en) * 1989-02-23 1989-04-05 Glaxo Canada Pharmaceutical compositions
SE9003902D0 (sv) * 1990-12-07 1990-12-07 Astra Ab Solid dosage forms of a drug
GB8925484D0 (en) * 1989-11-10 1989-12-28 Glaxo Group Ltd Process
WO1992004893A1 (fr) * 1990-09-13 1992-04-02 Smithkline Beecham Corporation Suspensions orales liquides non aqueuses
SE9003903D0 (sv) * 1990-12-07 1990-12-07 Astra Ab New pharmaceutical formulations
AU663695B2 (en) * 1990-12-21 1995-10-19 Richardson-Vicks Inc. Polyamine drug-resin complexes
US5272137A (en) * 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
JP3207494B2 (ja) * 1992-04-02 2001-09-10 ロート製薬株式会社 水性懸濁製剤
JP3278192B2 (ja) * 1992-04-03 2002-04-30 ロート製薬株式会社 徐放性液剤
GB9211148D0 (en) * 1992-05-26 1992-07-08 Smithkline Beecham Plc Novel treatment
GB9221414D0 (en) * 1992-10-13 1992-11-25 Glaxo Group Ltd Pharmaceutical compositions
CA2146999A1 (fr) * 1992-10-16 1994-04-28 Stephen John Douglas Compositions de ranitidine a amertume attenuee
EP0687174B1 (fr) * 1993-03-05 2001-06-13 Hexal Ag Complexes cristallins d'insertion de cyclodextrine de l'hydrochlorure de ranitidine, et leur procede de preparation
EP0620001A1 (fr) * 1993-04-16 1994-10-19 McNEIL-PPC, INC. Suspension pharmaceutique aqueuse et procédé pour sa préparation
GB9324409D0 (en) * 1993-11-27 1994-01-12 Smithkline Beecham Plc Novel composition
DK171127B1 (da) * 1994-04-22 1996-06-24 Gea Farmaceutisk Fabrik As Ranitidintablet med et hydroxypropylmethylcelluloseholdigt overtræk samt fremgangsmåde til at tilvejebringe dette overtræk
US5538737A (en) * 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
RU2131264C1 (ru) * 1996-06-04 1999-06-10 Московское производственное химико-фармацевтическое объединение им.Н.А.Семашко Противоязвенное средство в виде таблеток и способ его получения
US5980882A (en) * 1997-04-16 1999-11-09 Medeva Pharmaceuticals Manufacturing Drug-resin complexes stabilized by chelating agents
CA2305179A1 (fr) * 1997-09-30 1999-04-08 Daiichi Pharmaceutical Co., Ltd. Preparation orale
WO1999024072A1 (fr) * 1997-11-10 1999-05-20 Hisamitsu Pharmaceutical Co., Inc. Agent a liberation prolongee pour medicaments et composition pharmaceutique a liberation prolongee
JP4283355B2 (ja) * 1997-11-10 2009-06-24 久光製薬株式会社 薬剤用徐放化剤及びそれを含有した徐放性医薬組成物
RU2154469C2 (ru) * 1998-08-10 2000-08-20 Открытое акционерное общество фармацевтическая фирма "ЗДОРОВЬЕ" Способ получения таблеток ранитидина
RU2203048C2 (ru) * 1998-08-18 2003-04-27 Леонидов Николай Борисович Физически устойчивая рентгеноаморфная форма ранитидина гидрохлорида с повышенной противоязвенной активностью и способ ее получения
NZ516536A (en) * 1999-07-14 2003-09-26 Schering Plough Ltd Taste masking or oral quinolone liquid preparations using ion exchange resins
US6514492B1 (en) 1999-07-14 2003-02-04 Schering-Plough Veterinary Corporation Taste masking of oral quinolone liquid preparations using ion exchange resins
GB9930058D0 (en) * 1999-12-20 2000-02-09 Novartis Ag Organic compounds
US7067116B1 (en) * 2000-03-23 2006-06-27 Warner-Lambert Company Llc Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1
US20020031490A1 (en) * 2000-07-27 2002-03-14 Bellamy Simon Andrew Method for preparing resinates
EP1429728A1 (fr) * 2001-08-29 2004-06-23 SRL Technologies, Inc. Preparations a liberation prolongee
ATE396746T1 (de) * 2002-01-18 2008-06-15 Rohm & Haas Verwendung eines resinats zur herstellung einer formulierung zur beendigung des rauchens
US20050036977A1 (en) * 2003-08-11 2005-02-17 Dilip Gole Taste-masked resinate and preparation thereof
US20050142097A1 (en) * 2003-12-29 2005-06-30 Deepak Thassu Multiple active drug resin conjugate
US20050265955A1 (en) * 2004-05-28 2005-12-01 Mallinckrodt Inc. Sustained release preparations
JP2008546835A (ja) * 2005-06-28 2008-12-25 ユ セ ベ ソシエテ アノニム 複数の活性薬物−樹脂抱合体
CN101253179B (zh) * 2005-09-21 2010-12-29 株式会社钟根堂 S-氯吡格雷的树脂酸盐复合物及其制备方法
ATE536867T1 (de) 2006-03-16 2011-12-15 Tris Pharma Inc Modifizierte freisetzungsformulierungen mit arznei-ion-austausch-harzkomplexen
CN100411626C (zh) * 2006-08-28 2008-08-20 浙江大学 缓释型碘补充剂的制备方法
WO2008042218A1 (fr) * 2006-10-03 2008-04-10 Tris Pharma, Inc. Préparation comprenant un complexe de résine échangeuse d'ions minéraux
CN100450548C (zh) * 2006-12-22 2009-01-14 江苏奥赛康药业有限公司 一种波拉克林树脂组合物的口腔贴片及其制备方法
MX2010003928A (es) * 2007-10-11 2010-09-10 Philip Morris Prod Producto de tabaco sin humo.
WO2009102830A1 (fr) * 2008-02-13 2009-08-20 Eurand Inc Compositions de comprimés de ranitidine se délitant oralement et leurs procédés de fabrication
JP5560701B2 (ja) * 2008-12-26 2014-07-30 ライオン株式会社 ラニチジン含有医薬固形製剤及びラニチジン担持粒子の製造方法
JP5412966B2 (ja) * 2009-06-08 2014-02-12 ライオン株式会社 粒状製剤
US8357398B2 (en) * 2009-10-21 2013-01-22 Alitair Pharmaceuticals Inc. Benzonatate compositions and methods of use
CN102138915A (zh) * 2011-03-28 2011-08-03 于晓勇 一种口服药物制剂及其制备方法
CN102198118B (zh) * 2011-03-28 2012-08-29 于晓勇 一种治疗呕吐的口腔药物制剂及其制备方法
AU2013302657B2 (en) 2012-08-15 2018-08-09 Tris Pharma, Inc. Methylphenidate extended release chewable tablet
WO2018083583A1 (fr) * 2016-11-01 2018-05-11 Johnson & Johnson Consumer Inc. Forme posologique pharmaceutique orale liquide comprenant un antagoniste du récepteur h2 à l'histamine et un antiacide
CA3095103A1 (fr) 2018-04-27 2019-10-31 Johnson & Johnson Consumer Inc. Forme galenique pharmaceutique orale liquide

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR803638A (fr) * 1935-06-21 1936-10-05 Système de freinage pour portes coulissantes
US4795641A (en) * 1987-08-20 1989-01-03 Eastman Kodak Company Polymer blends having reverse phase morphology for controlled delivery of bioactive agents

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2828207A (en) * 1955-11-14 1958-03-25 Du Pont Fortification of feed
US2990332A (en) * 1958-04-02 1961-06-27 Wallace & Tiernan Inc Pharmaceutical preparations comprising cation exchange resin adsorption compounds and treatment therewith
US2970053A (en) * 1958-10-28 1961-01-31 Pfizer & Co C Oleandomycin resin adsorbate
US3138525A (en) * 1961-06-16 1964-06-23 Hoffmann La Roche Castor wax-amprotropine-resin compositions
US3949068A (en) * 1964-02-20 1976-04-06 University Of Alabama In Birmingham Medical And Educational Foundation Pharmaceutical compositions
GB1180233A (en) * 1966-02-23 1970-02-04 Jean Astruc Modified Spiramycin
US3624209A (en) * 1966-12-28 1971-11-30 Bristol Myers Co Composition for treatment of gastro-intestinal disorders
GB1218102A (en) * 1968-03-15 1971-01-06 Philips Nv Improvements in medicaments comprising drug/ion-exchange resin compounds
JPS5146154B2 (fr) * 1972-05-11 1976-12-07
GB1462356A (en) * 1973-07-10 1977-01-26 Beecham Group Ltd Pharmaceutical compositions
JPS51125708A (en) * 1974-07-23 1976-11-02 Beecham Group Ltd Production of betaalactam antibiotic complex
GB1565966A (en) * 1976-08-04 1980-04-23 Allen & Hanburys Ltd Aminoalkyl furan derivatives
CY1306A (en) * 1980-10-01 1985-12-06 Glaxo Group Ltd Aminoalkyl furan derivative
IL63968A (en) * 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
EP0077529B1 (fr) * 1981-10-16 1985-07-17 Sanol Schwarz GmbH Formule médicamenteuse
GB8313217D0 (en) * 1983-05-13 1983-06-22 Glaxo Group Ltd Pharmaceutical compositions
NZ215069A (en) * 1985-03-01 1988-06-30 Reckitt & Colmann Prod Ltd Pharmaceutical composition with histamine h 2 -receptor antagonist
US4788055A (en) * 1985-12-09 1988-11-29 Ciba-Geigy Corporation Resinate sustained release dextromethorphan composition
JPS6369038A (ja) * 1986-09-10 1988-03-29 Canon Inc 光カ−ド記録媒体

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR803638A (fr) * 1935-06-21 1936-10-05 Système de freinage pour portes coulissantes
US4795641A (en) * 1987-08-20 1989-01-03 Eastman Kodak Company Polymer blends having reverse phase morphology for controlled delivery of bioactive agents

Also Published As

Publication number Publication date
HK45094A (en) 1994-05-13
ES2011573A6 (es) 1990-01-16
CA1337272C (fr) 1995-10-10
SE508343C2 (sv) 1998-09-28
AU3461789A (en) 1989-11-16
GB8910706D0 (en) 1989-06-28
HU204994B (en) 1992-03-30
AT401614B (de) 1996-10-25
HU211592A9 (en) 1995-12-28
DK168934B1 (da) 1994-07-11
FI892248L (fi) 1989-11-12
FR2631232A1 (fr) 1989-11-17
IL90245A0 (en) 1989-12-15
IE60722B1 (en) 1994-08-10
IL90245A (en) 1994-04-12
FI892248A0 (fi) 1989-05-10
SE8901671L (sv) 1989-11-12
CH679011A5 (fr) 1991-12-13
CY1781A (en) 1995-10-20
IT1232831B (it) 1992-03-05
CN1027133C (zh) 1994-12-28
FI92060B (fi) 1994-06-15
NO175131B (no) 1994-05-30
JP2944678B2 (ja) 1999-09-06
NO891906L (no) 1989-11-13
NO175131C (no) 1994-09-07
SE8901671D0 (sv) 1989-05-10
DK229489D0 (da) 1989-05-10
MX15983A (es) 1993-10-01
KR890016968A (ko) 1989-12-14
DE3915347A1 (de) 1989-11-16
PH27612A (en) 1993-08-31
YU97189A (en) 1990-06-30
GR1000358B (el) 1992-06-30
US5032393A (en) 1991-07-16
PT90523A (pt) 1989-11-30
CN1037651A (zh) 1989-12-06
GR890100314A (en) 1990-03-12
RU2033155C1 (ru) 1995-04-20
YU47674B (sh) 1996-01-08
NL8901188A (nl) 1989-12-01
PL279377A1 (en) 1990-01-22
DE3915347C2 (de) 1994-11-03
PT90523B (pt) 1994-10-31
ATA112089A (de) 1996-03-15
MX173349B (es) 1994-01-22
FI92060C (fi) 1994-09-26
GB2218333A (en) 1989-11-15
FR2631232B1 (fr) 1993-11-19
NZ229064A (en) 1991-12-23
LU87515A1 (fr) 1990-06-12
AU624613B2 (en) 1992-06-18
HUT50036A (en) 1989-12-28
GB2218333B (en) 1991-11-06
JPH02111719A (ja) 1990-04-24
NO891906D0 (no) 1989-05-10
IE891527L (en) 1989-11-11
SG48194G (en) 1994-11-25
DK229489A (da) 1989-11-12
MY104013A (en) 1993-10-30
IT8947938A0 (it) 1989-05-10

Similar Documents

Publication Publication Date Title
ATE50433T1 (de) Pharmazeutische zusammensetzungen.
BE1002249A4 (fr) Compositions pharmaceutiques.
IT8220781A0 (it) Bifosfonati farmacologicamente attivi, procedimento per la loro preparazione e relative composizioni farmaceutiche.
CO4600739A1 (es) Formulaciones liquidas orales a base de alendronato
DE69532415D1 (de) Schmelzextrudierte oral verabreichbare opioidformulierungen
DZ1077A1 (fr) Nouvelles préparation pharmaceutique pour administration orale.
IE862554L (en) Pharmaceutical compositions
FR2582513B1 (fr) Compositions pharmaceutiques contenant de l'alfuzosine
EP0208623A3 (fr) Utilisation de poly- et oligosaccharides pour l'obtention de médicaments actifs dans les pathologies du tissu conjonctif
BR9706537A (pt) Composição farmacêutica para administração por via oral
HUT77702A (hu) Vitamin és kalcium terápiás kombinációja egységes galenikus tabletta formában, eljárás előállítására és alkalmazása
NZ511085A (en) Oral pharmaceutical compositions containing buprenorphin
CA2338794A1 (fr) Nouvelle formulation orale d'agonistes ou d'antagonistes de 5-ht4
SE8701087L (sv) Plackhemmande oral komposition
BG103005A (en) Active substance-containing sedimented silicic acids
DK0437294T3 (da) Orale farmaceutiske præparater i enhedsdosisform
ATE187334T1 (de) Pharmazeutische zusammensetzung in form eines gels mit chondroitinsulfat in salzform zur oralen verabreichung
ES2040239T3 (es) Procedimiento de preparacion de una composicion farmaceutica para la profilaxis y terapia de la ulcera gastrica.
BE902796A (fr) Ester d'acetyl carnitine, sa preparation et son utilisation.
FR2694558B1 (fr) Monohydrate du sel disodique de l'acide 4-chlorophénylthiométhylène bisphosphonique, sa préparation, les compositions pharmaceutiques en contenant.
PT88145A (pt) Procede pour la preparation de composition pharmaceutique destinee a la prevention et au traitement des maladies bacteriennes ou virales
IT8621097A0 (it) Composizioni farmaceutiche. derivato di timo attivo per via orale, procedimenti per la sua preparazione e relative
EP0093497A3 (fr) Traitement anthelminthique
BE902055A (fr) Preparations pharmaceutiques.
AU2335284A (en) Synergistic composition of hydroxyzine and salts thereof with NSAIDs